Overview

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2029-03-29

Target enrollment:

Participant gender:

Summary

This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable EGFRm Non-Small Cell Lung Cancer

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Carboplatin
Osimertinib
Pemetrexed